Roflumilast is a PDE4 inhibitor that was approved by the FDA and the European Medicines Agency (EMA) as an oral treatment of chronic obstructive pulmonary disease [10]. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.